Welcome to our dedicated page for Pressure Bio news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on Pressure Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pressure Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pressure Bio's position in the market.
Pressure BioSciences (PBIO) announced a partnership with Vita-Forte to create a highly bioavailable multi-antioxidant oral spray using PBIO's UltraShear Technology. The product will combine potent oil-based antioxidants like Acai, Curcumin, and CoQ10 into a fast-absorbing, nanoemulsified spray. Expected to be available by Fall 2024, this product aims to improve antioxidant absorption significantly. Vita-Forte, a leading distributor of superfood ingredients with annual revenues exceeding $20 million, will leverage its extensive customer base to facilitate market introduction and acceptance. This collaboration promises to deliver improved effectiveness and potency for nutraceutical products.
Pressure BioSciences (OTCQB: PBIO) will host a teleconference on June 20, 2024, at 4:30 PM ET to provide updates on various business and financial topics. Key points include the FY 2023 financial and business results, FY 2024 outlook, status of the company's relocation to a new manufacturing facility, and updates on a new Joint Venture Program. The company will also discuss product expansion plans, including new nanoemulsified products expected to release in Q3/Q4 2024, and the placement of first-generation UltraShear benchtop equipment in multiple cannabis companies for THC edible products. Stakeholders can listen live or via replay on the company's website.
Pressure BioSciences (OTCQB: PBIO) announced a teleconference to update stakeholders on June 19, 2024, at 4:30 PM ET. Key topics include FY 2023 financial and business results, the FY 2024 outlook, the status of the company's new manufacturing facility, and updates on Uncle Bud’s Health and Wellness product expansion. New nanoemulsified products are expected to launch commercially in Q3/Q4 2024, including next-generation skincare with nano-retinol, a nootropic enhancer, and a best-in-class antioxidant cocktail. Additionally, the placement of the 1st Generation UltraShear benchtop equipment into cannabis companies will be discussed. The teleconference will include a presentation and a Q&A session. Interested parties can participate live or access a replay via the company's website.
FAQ
What is the current stock price of Pressure Bio (PBIO)?
What is the market cap of Pressure Bio (PBIO)?
